anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to compositions and methods for treating glycogen storage disease, such as GSD II. A human activator enzyme, termed ASA, of acid a a-glycosidase, (GAA) or acid maltase, a lysosomal enzyme, is specifically defined and characterized. The AGA has been found to increase the activity of human acid α glycosidase activity to at least 10-fold, relative to the activity of GAA in the absence of the activator protein. The invention thus also provides for a method of increasing the activity of GAA, particularly through the action of AGA. The AGA has an approximate molecular weight of 25-30 kD, and is found to be heat stable. In addition, the AGA is found to have an extended shelf life without significant loss of ability to activate GAA. The invention further reports other enzymes such as β-Fucosidase, β-Lactase, and β-Galactosidase, that provide enhancement of enzymatic activity nine-fold, six-fold, and five-fold, for breakdown of their respective substrate protein. These enzymes are non-lysosomal enzymes. These are anticipated to be useful in treatment of disease related to reduced enzymatic activity levels in an animal.
The current standard-of-care utilizes corticosteroids to down-regulate the inflammatory state in patients with asthma. However, corticosteroids have many side effects and are not universally effective. New safe anti-inflammatory agents are needed to help modulate the disease. Peroxisome proliferator-activated receptor agonists are widely used to manage diabetes mellitus, another common chronic disease. These agents have been study models and have been shown to have anti-inflammatory effects in lung tissue. Case reports have noted improvement in asthma symptoms in patients being treated with these agents. These agents are ideally placed for human research given their long record of safe use in the treatment of type 2 diabetes.
Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles. The total duration of treatment is up to approximately 2 years.
We encountered a rare case of appendiceal carcinoma associated with Amyand's hernia, which was difficult to diagnose preoperatively. A 74-year-old man presented to our hospital with right lower abdominal pain. A hard mass was palpable in the right lower abdomen, and blood tests showed a slightly elevated inflammatory response. Computed tomography revealed a 7 × 5 cm mass with indistinct borders and heterogeneous internal density extending from the cecum to the right lower abdominal wall. We diagnosed appendiceal abscess, however, percutaneous biopsy which was performed for differential diagnosis with appendiceal carcinoma showed no malignancy. Thereafter, the patient was followed up. Two months later, a blood test showed insignificant changes in the inflammatory response and a high serum carcinoembryonic antigen level (48.6 ng/mL). An ultrasound showed a mass contiguous to the appendix, extending to the abdominal wall, with abundant blood flow signals. Fluorodeoxyglucose-positron emission tomography showed a high accumulation of fluorodeoxyglucose in the mass. Four months after the initial visit, the patient had an open ileocecal resection combined with an abdominal wall resection based on the preoperative diagnosis of appendiceal carcinoma invading the abdominal wall. During laparotomy, an enlarged appendix tip extended from the internal inguinal ring outside the inferior epigastric artery to the abdominal wall. Histopathological examination of the appendiceal tumor revealed well-differentiated adenocarcinoma, T4b (abdominal wall), N0, Ly0, and V0. When a right lower abdominal mass extends from the cecum to the abdominal wall, appendiceal tumors associated with Amyand's hernia should be considered.
Healthy Living Course (HLC) an 8-week psycho-educational program that consists of lectures and discussion on healthy living, stress management, time management, and unhealthy behaviors (e.g. smoking, drinking).
PURPOSE:To offer the best display conditions in accordance with the photographing conditions from the beginning of display by storing previously the photographing conditions as a parameter in terms of the display conditions of the image decided by an operator. CONSTITUTION:An inquiry is given to a photographing/displaying condition storage 3 based on the photographing conditions of the input image. Then the photographing conditions are stored as a parameter by reference to the past data and at the same time the display conditions that are used most frequently to the photographing conditions are extracted. Thus a controller 1 applies the image processing to the image data via an image processor 10 based on the extracted display conditions. The processor 10 applies the processes like the emphasis of frequency, etc., via a frequency processor 4 and then applies the gammacorrection and a density window process to the display image data via a magnification/reduction processor 5. Thus the image is displayed on a CRT display 7 at an optimum density level. Then an operator adds the image processing as necessary via a keyboard 8 after display of the image in order to change the display conditions.
The present invention relates to an antithrombotic composition containing an Asian hornet (Vespa velutina nigrithorax) extract as an active ingredient, and more specifically, to a pharmaceutical composition and health functional food for preventing or treating/improving thrombosis through inhibition of blood coagulation and inhibition of platelet aggregation, which contains the ethyl acetate fraction of an ethanol extract of Asian hornet as an active ingredient. As demonstrated through embodiments herein, the Asian hornet extract as an active ingredient in the pharmaceutical composition and health functional food for preventing or treating thrombosis of the present invention exhibits strong anticoagulant activity by inhibiting enzymes related to thrombus formation and blood coagulation factors, and at the same time exhibits antithrombotic activity by inhibiting platelet aggregation. In addition, the antithrombotic active substances in the Asian hornet extract do not have hemolytic activity in human red blood cells but have excellent thermal stability. Since the Antithrombotic active substances do not lose their inhibitory effect on enzymes related to thrombus formation and blood coagulation factors even under acidic conditions of pH 2 and in plasma, it is expected to be used for the prevention and treatment of thromboses such as ischemic stroke and hemorrhagic stroke by improving blood circulation. The active ingredient can be processed into various forms such as extracts, powders, pills, tablets, and the like and has excellent effects when prepared in a form that can be taken at all times. Thus, the present invention is a very useful invention in the pharmaceutical and food industries.
For the first 14 days of therapy, participants will receive Azithromycin 250mg PO daily as monotherapy. Beyond day 14, all participants will receive guideline-based standard multi-drug therapy for Mycobacterium avium lung disease, as dictated by the physicians treating the participants.
Patients undergoing flexible bronchoscopy (FB) experience procedure-related symptoms. Current guidelines of FB recommend sedation to all patients undergoing FB, except when there are contraindications. Propofol plus an opioid is the common combination used to improve patient tolerance and satisfaction during FB. However, controversy about combining propofol and opioids persists because of the risk of over-sedation and cardiopulmonary depression, especially for the time-consuming endobronchial ultrasound (EBUS)-guided transbronchial needle aspiration (TBNA). Similar with other published data, around 40% of hypoxemia event was observed during FB sedation in the investigators' hospital. Dexmedetomidine, is a sedative agents via α2 adrenergic agonist, with little respiratory suppression. It has been applied in patients with mechanical ventilation, undergoing gastroendoscopy and extracorporal shockwave lithotripsy. Little evidences are available for Dexmedetomidine in sedation for EBUS-TBNA.

In this study, the investigators will evaluate the safety and feasibility of Dexmedetomidine for sedation of EBUS-TBNA comparing to Propofol for sedation of EBUS-TBNA. Generally, the FB sedation can divided into three parts: the induction (from starting sedative administration to insertion of bronchoscope); the maintenance ( from insertion of bronchoscope to its removal) and the recovery (from bronchoscope removal to patients gain consciousness). The primary endpoint is the proportion of patients with hypoxemia during maintenance of sedation. the investigators will also observe the other sedative outcomes, e.g. blood pressure, sedative drug dosing and patient tolerance and cooperation. The present study will also observe the association between brain perfusion and sedative outcomes via non-invasive monitor. Based on the unique pharmacokinetic property of Dexmedetomidine and the real-time brain perfusion monitor, Dexmedetomidine-based sedation may provide better safety profile for EBUS-TBNA than propofol and discover novel connection between sedative outcomes and brain perfusion.
Falls and frailty status are often associated with a decline in physical capacity and multifactorial assessment is highly recommended. Based on the functional and biomechanical parameters measured during clinical tests with an accelerometer integrated into smart eyeglasses, the purpose was to characterize a population of older adults through an unsupervised analysis into different physical performance groups. A total of 84 participants (25 men and 59 women) over the age of sixty-five (age: 74.17 ± 5.80 years; height: 165.70 ± 8.22 cm; body mass: 68.93 ± 13.55 kg) performed a 30 s Sit-to-Stand test, a six-minute walking test (6MWT), and a 3 m Timed Up and Go (TUG) test. The acceleration data measured from the eyeglasses were processed to obtain six parameters: the number of Sit-to-Stands, the maximal vertical acceleration values during Sit-to-Stand movements, step duration and length, and the duration of the TUG test. The total walking distance covered during the 6MWT was also retained. After supervised analyses comparison (i.e., ANOVAs), only one of the parameters (i.e., step length) differed between faller groups and no parameters differed between frail and pre-frail participants. In contrast, unsupervised analysis (i.e., clustering algorithm based on K-means) categorized the population into three distinct physical performance groups (i.e., low, intermediate, and high). All the measured parameters discriminated the low- and high-performance groups. Four of the measured parameters differentiated the three groups. In addition, the low-performance group had a higher proportion of frail participants. These results are promising for monitoring activities in older adults to prevent the decline of physical capacities.
Methods, systems, and computer-readable media are provided to detect similarities between two or more clinical documents. It is determined that a clinician is currently inputting data into a first clinical document that is associated with a patient. A selectable option is provided on a user interface into which the clinician is currently inputting the data. An indication is received that the selectable option has been selected by the clinician. An algorithm is applied to identify the second clinical document from a plurality of clinical documents. At least a portion of the inputted data in the first clinical document and at least a portion of data in the second clinical document are transformed to generate a new representation of the first clinical document that indicates the similarities that are potentially inaccurate or inappropriate between the first clinical document and the second clinical document.
PURPOSE OF REVIEW: This review meticulously delves into existing literature and recent findings to elucidate the intricate link between obesity and clonal hematopoiesis of indeterminate potential (CHIP) associated clonal hematopoiesis. It aims to enhance our comprehension of this multifaceted association, offering insights into potential avenues for future research and therapeutic interventions.
RECENT FINDINGS: Recent insights reveal that mutations in CHIP-associated genes are not limited to symptomatic patients but are also present in asymptomatic individuals. This section focuses on the impact of obesity-induced inflammation and fatty bone marrow (FBM) on the development of CHIP-associated diseases. Common comorbidities such as obesity, diabetes, and infection, fostering pro-inflammatory environments, play a pivotal role in the acceleration of these pathologies. Our research underscores a notable association between CHIP and an increased waist-to-hip ratio (WHR), emphasizing the link between obesity and myeloid leukemia. Recent studies highlight a strong correlation between obesity and myeloid leukemias in both children and adults, with increased risks and poorer survival outcomes in overweight individuals.
SUMMARY: We discuss recent insights into how CHIP-associated pathologies respond to obesity-induced inflammation, offering implications for future studies in the intricate field of clonal hematopoiesis.
The invention relates to clopidogrel hydrogen sulfate tablets and a preparation method thereof. The preparation is composed of: an active component of clopidogrel hydrogen sulfate, a filling material, a diluent, an adhesive, a disintegrating agent, a lubricant, and a flow aid. The preparation method provided by the invention can satisfy production requirements of tablet industrialization. With the method, medicine quality is controllable. The prepared clopidogrel hydrogen sulfate tablets satisfy quality standard requirements of United States Pharmacopoeia USP 32 version. The stability of the medicine is ensured, and the medicine can be stored for more than 2 years under room temperature.
Limited data indicate that snakebite survivors have persistent musculoskeletal disability. We assessed the pain and functional disability at hospital discharge and after 3 months in 47 patients treated for snakebite envenoming and with at least a specified amount of local swelling at the time of hospital discharge, using the numerical pain rating scale and the Patient-Specific Functional Scale (PSFS). Russell's viper was the most common biting snake species identified. At hospital discharge, the median pain score was 2 (0-3); 9 (19%) patients reported mild persisting pain at 3 months. The median PSFS score at hospital discharge was 3.7 (3.3-4.0), which improved to 8.3 (6.3-9.0) on follow-up (P <0.001); 32 (68%) patients had a PSFS score of 8.9 or below on follow-up. We conclude that snakebite envenoming could be associated with persisting functional disability at 3 months even in the absence of local complications such as skin necrosis and compartment syndrome.
Subjects aged at enrolment between 3 and 36 months, 36 months excluded, received 2 doses of Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A vaccine or GSK Biologicals' monovalent A/Indonesia/5/2005 (H5N1) vaccine adjuvanted) at Days 0 and 21. Influenza A (H5N1) Virus monovalent vaccine was administered intramuscularly. For children aged up to 12 months, 12 months excluded (\< 12 months), Dose 1 was administered in the left anterolateral thigh and Dose 2 in the right anterolateral thigh. For children older than (\>=) 12 months, Dose 1 was administered in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
The recommended adult oral dosage for duodenal ulcer is 1 g (10 mL/2 teaspoons) four times per day. CARAFATE should be administered on an empty stomach. Active Duodenal Ulcer.

Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after sucralfate.

While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.

In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (See ). Elderly:PRECAUTIONS Geriatric Use

Call your doctor for medical advice about side effects. You may report side effects to Aptalis Pharma US, Inc. at 1-800-472-2634 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Systems and methods for evaluating competency of a healthcare professional are provided. Systems and methods for evaluating competence of a healthcare professional using linear narrative progress are provided. The system includes a virtual console and an evaluation tool. The virtual console is configured to present the clinical profile to the healthcare professional and to display a series of digital images and questions to the healthcare professional based on the clinical profile. The virtual console is also configured to receive a response to each question. The virtual console is further configured to display corrective instructions to the healthcare professional after receiving the response to the critical issue, wherein the subsequent digital image and issue are based on the corrective instructions. The evaluation tool is configured to evaluate the healthcare professional's interpretation of each of the plurality of digital images.
Infection with Schistosoma japonicum (S. japonicum) is an important zoonotic parasitic disease that causes liver fibrosis in both human and domestic animals. The activation of hepatic stellate cells (HSCs) is a crucial phase in the development of liver fibrosis, and inhibiting their activation can alleviate this progression. Total flavonoids of litchi seed (TFL) is a naturally extracted drug, and modern pharmacological studies have shown its anti-fibrotic and liver-protective effects. However, the role of TFL in schistosomiasis liver fibrosis is still unclear. This study investigated the therapeutic effects of TFL on liver fibrosis in S. japonicum infected mice and explored its potential mechanisms. Animal study results showed that TFL significantly reduced the levels of Interleukin-1β (IL-1β), Tumor Necrosis Factor-α (TNF-α), Interleukin-4 (IL-4), and Interleukin-6 (IL-6) in the serum of S. japonicum infected mice. TFL reduced the spleen index of mice and markedly improved the pathological changes in liver tissues induced by S. japonicum infection, decreasing the expression of alpha-smooth muscle actin (α-SMA), Collagen I and Collagen III protein in liver tissues. In vitro studies indicated that TFL also inhibited the activation of HCSs induced by Transforming Growth Factor-β1 (TGF-β1) and reduced the levels of α-SMA. Gut microbes metagenomics study revealed that the composition, abundance, and functions of the mice gut microbiomes changed significantly after S. japonicum infection, and TLF treatment reversed these changes. Therefore, our study indicated that TFL alleviated granulomatous lesions and improved S. japonicum induced liver fibrosis in mice by inhibiting the activation of HSCs and by improving the gut microbiomes.
PURPOSE: Anti-infectious pyrido(1,2-A)pyrimidines are provided to prevent the proliferation of Mycobacterium tuberculosis bacillus in a host macrophage. CONSTITUTION: A compound of chemical formula 1 and a pharmaceutically acceptable salt thereof are provided. A compound of chemical formula 2 and a pharmaceutically acceptable salt thereof are provided. A compound of chemical formula 3 and a pharmaceutically acceptable salt thereof are provided. A compound of chemical formula 4 and a pharmaceutically acceptable salt thereof are provided. The compounds are used for treating bacterial infection. The bacterial infection is tuberculosis. A pharmaceutical composition contains one compound among the compounds and a pharmaceutically acceptable diluents, carrier, or excipient.
A pharmaceutical compn. with controlled release of active material in the intestinal tract was described. The compn, consisted of a tablet nucleus of active material with a coating resistant to gastric juices, and an outer layer of active material, which enabled a quick release of drug into the blood stream via the stomach and a high initial concn. in the blood. This high blood level is maintained by a further release of drug in the small intestine. A typical tablet comprised; 1) a nucleus of 4-(2-hydroxy-3-isopropylaminopropoxy) indole (I) 5, Na lauryl sulfate 2.5, Et cellulose 4.5, microcryst. cellulose 7.0, mannitol 27.5; and 2) gastric juiceinsol. layer of hydroxypropyl Me cellulose phthalate, etc.
Diabetes and cancer are common diseases and easily occur simultaneously in the same patient who is required to take anti-diabetic drugs while receiving anti-tumor drug treatment. In recent years, immunotherapy has made a significant progress in the field of cancer treatment, however, it is unclear whether diabetes drugs affect immunotherapy. The research explores the influence of 6 common diabetes drugs such as acarbose, sitagliptin, metformin, glimepiride, pioglitazone and insulin on an immune checkpoint inhibitor PD1 antibody in tumor treatment through a mouse colon cancer model and a melanoma model. We found that acarbose and sitagliptin enhanced the inhibition of the tumor by the PD1 antibody, and that metformin had no effect on the inhibition of the PD1 antibody, and that glimepiride, pioglitazone and insulin attenuated the inhibition of the tumor by the PD1 antibody. Our study suggests that cancer patients receiving PD1 antibody treatment need careful consideration in selecting diabetes drugs, especially acarbose, can significantly inhibit tumor growth and enhance the therapeutic effect of PD1 antibody, and can be considered for application in tumor treatment. On this basis, further clinical trials are expected to be performed.
OBJECTIVE: Tyrosine kinase inhibitors (TKIs) have successfully changed the natural course of chronic myeloid leukaemia (CML). Although they are highly effective drugs, their clinical benefit is conditioned by adherence. This study aims to analyse the adherence of CML patients treated with TKIs and to identify the main factors influencing their adherence to TKIs treatment.
MATERIAL AND METHODS: An 8-month prospective, observational, multicentre study which included patients diagnosed with CML on treatment with TKIs attending the outpatient departments (OPD) of the Pharmacy Services of the participating hospitals. Adherence was assessed using two methods: the Simplified Medication Adherence Questionnaire (SMAQ) and the register of treatment dispensations from the OPDs. To analyse the predictors of adherence, a questionnaire was developed to report demographic and socio-economic information on the patients.
RESULTS: A total of 130 patients enrolled in this study. Adherence rate was 56.9% (n = 74) among individuals, not conditioned by the type of drug used: imatinib (54.8%), nilotinib (63.6%) or dasatinib (54.3%) (p = 0.67). The patient educational level (p = 0.047) and employment status (p = 0.028) were predictors of non-adherence to treatment.
CONCLUSIONS: Adherence is one of the most relevant parameters affecting the effectiveness of highly effective chronic treatments. Approximately half of our patients showed inadequate adherence to treatment with TKIs, with employment status and the individual's level of education emerging as the determining factors.
Obese subjects will receive a complex nutrient drink (Ensure Plus; 17 % protein, 30 % fat and 53 % carbohydrate, 1 kcal/mL). Nutrient intake will be stopped when subjects had reached maximal or unbearable satiation; the time needed to reach the maximal level of satiation (tmax) and the quantity of volume drunk will be recorded and calorie intake calculated.